PE outside the acceptance range [Study As­sess­ment]

posted by aanrin – United Arab Emirates, 2015-08-24 11:08 (3464 d 06:12 ago) – Posting: # 15326
Views: 9,305

Hi Helmut,

Thanks for your kind reply.please find my comments below for your advice.

From the results obtained from the BE studies the reference product achieves mean AUCt values as high as 3377.07 ng·h/ml in fasting conditions and as low as 1382.98 ng·h/ml in fed condition.

Based on the Reference product’s claim in the SmPC, stating that decreased and delayed absorption of esomeprazole due to food effect has no significant influence on its clinical efficacy, then the clinical efficacy should be guaranteed within the range 3377.07 – 1382.98 ng·h/ml.

In another word, the mean AUCt values of the Test product are well within the reference product range 3377.07 – 1382.98 ng·h/ml. Therefore, the clinical efficacy of the test product should be guaranteed when it was taken under fed condition.

So in this case a additional clinical study is required ? or the same BE study is enough for the submission to the regulatory as Generic.?

Complete thread:

UA Flag
Activity
 Admin contact
23,381 posts in 4,914 threads, 1,663 registered users;
30 visitors (0 registered, 30 guests [including 8 identified bots]).
Forum time: 16:20 CET (Europe/Vienna)

Science is built up with facts, as a house is with stones.
But a collection of facts is no more a science
than a heap of stones is a house.    Henri Poincaré

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5